DiscGenics’ proprietary Discogenic cells will be assessed in use with the VA’s whole, tissue-engineered endplate-modified disc-like angle ply structure, called eDAPS. They are living tissue-engineered resorbable polymer vertebral disc implants mimicking natural disc function and structure.
The eDAPS are designed to replace degenerated discs for patients with late-stage intervertebral disc degeneration.
“A biologic disc replacement in lieu of existing mechanical devices would continue to change the paradigm of spine care away from a device-centric model to one of disease modification through biologic and cell-based treatments,” Kevin Foley, MD, chief medical officer of DiscGenics, said in the release.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
